De Novo KRAS G12C–Mutant SCLC: A Case Report

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

Saved in:
Bibliographic Details
Published in:JTO clinical and research reports 2022-05, Vol.3 (5), p.100306, Article 100306
Main Authors: Balbach, Meridith L., Eisenberg, Rosana, Iams, Wade T.
Format: Article
Language:English
Subjects:
Case Report
KRAS G12C
Small cell lung cancer
Targeted therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?
ISSN:2666-3643
2666-3643
DOI:10.1016/j.jtocrr.2022.100306